Vertex back for second deal with Genomics, leads series B

Machine learning company Genomics plc (Oxford, U.K.) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) partnered in a target discovery deal on a newsy Thursday that also saw Genomics close a Vertex-led, oversubscribed series B round at £25 million ($31.9 million).

Vertex contributed £10.5 million ($13.4 million) to the round, which included participation from fellow new investor Oxford Sciences Innovation. Existing investors in the round included IP Group plc (LSE:IPO), Woodford Investment Management, Invesco Perpetual, Lansdowne Partners and Tanarra...